Meeting a Public Health Need at the Point-of-Care

Cover Image for Meeting a Public Health Need at the Point-of-Care
Posted underSexual Health

This past year, there have been more than 30,000 reported cases of mpox in the U.S. alone, and countless more that have gone undetected. While the medical community has made great strides in managing this public health crisis, including gaining a better understanding of the virus and scaling vaccination efforts to support vulnerable communities, the Centers for Disease Control and Prevention (CDC) recently issued an alert that this summer season could lead to a resurgence of mpox. 

To combat this, the CDC is urging clinicians to be on alert for new cases of the highly contagious disease and, if mpox is suspected, to test — even if a patient previously had mpox or is vaccinated against the disease. 

Due to this public health need, we developed a highly accurate molecular mpox test that can be performed in authorized laboratories or by healthcare professionals in CLIA-certified patient care settings such as a doctor’s office, delivering results in just 25 minutes. In clinical sample testing, the test demonstrated 100% concordance with the FDA-cleared CDC mpox test. The Cue Mpox (Monkeypox) Molecular Test received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) in March, and is now available for professional use in point-of-care settings across the country.  

Enabling the early and accurate detection of the mpox virus is critical to preventing further spread by identifying cases and isolating infected individuals and to providing timely medical intervention. As we have seen with other public health crises, testing helps healthcare professionals to identify emerging hotspots and enables the prioritization of resources to those communities. At an individual level, patients benefit from confirming their status, seeking appropriate care, and thus taking appropriate precautions to prevent further transmission.

At Cue, we envision a world where access to testing and actionable diagnostic data is ubiquitous and convenient for all. The Cue Mpox (Monkeypox) Molecular Test launch is one more step towards that world. Our work here is focused on making that vision a reality, by developing and offering a diagnostic-led healthcare ecosystem that provides a seamless experience from testing to treatment. 

This information is presented in summary form, general in nature, and for informational purposes only. Content is not intended nor recommended to substitute for professional medical advice. For personal medical advice, always consult your doctor or other qualified healthcare professional. The tests offered are subject to change and subject to availability. Due to state restrictions, this Cue Product is not available for individuals located in the state of New York. Other state restrictions may apply for specific tests. Please refer to our support page for detailed product terms and conditions.



More Stories

Cover Image for RSV in Children: Prevention, Symptoms, and New Vaccines

RSV in Children: Prevention, Symptoms, and New Vaccines

Every parent’s priority is their child’s health, especially while navigating through the myriad of concerns that childhood brings. Among these concerns, Respiratory Syncytial Virus (RSV) emerges as a formidable challenge in the lives of infants and young children. This article, “RSV in Children: Prevention, Symptoms, and New Vaccines”, is your comprehensive guide to understanding this […]

Cover Image for Empower Health: Transform Your Team with Powerful At-Home Testing

Empower Health: Transform Your Team with Powerful At-Home Testing

In today’s fast-paced and ever-evolving workplace landscape, keeping employees healthy has become a top priority for companies. As we navigate the complexities of modern work environments, particularly with the rise of remote and hybrid models, ensuring the well-being of your team has taken on a new level of importance. Enter the game-changer: at-home health testing.  […]